WSGR logoWSGR logo

Wilson Sonsini Goodrich & Rosati's legacy closely traces the birth and evolution of Silicon Valley.

For nearly six decades, Wilson Sonsini has represented the technology pioneers associated with virtually every milestone innovation.

Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.

Read More About Us

Our track record has earned accolades from clients and colleagues alike.

Meet Our Antitrust Litigation Team
Careers

We look for the best and brightest of tomorrow and develop careers from the ground up.

News and Featured Insights

Alerts
Expansion of U.S. Export Controls on Huawei-Designed or Produced Items
Alerts
CFIUS Serves Up Proposed Changes to Mandatory Filing Rules: Bon Appétit!
Alerts
IRS Extends Safe Harbor for Renewable Energy Projects
Leading Matters
Client Highlights
Wilson Sonsini Advises Babylon on Investment in Higi
On May 27, 2020, UK-based Babylon, a technology company providing accessible and affordable healthcare by combining AI with doctors, announced its investment in consumer health engagement company Higi, a startup that owns and operates more than 10,000 FDA-cleared self-service Smart Health Stations. Wilson Sonsini Goodrich & Rosati advised Babylon in the investment.
Learn More
Client Highlights
Firm Represents CalciMedica in $15 Million Series C to Support Clinical Trials in Patients with COVID-19
On May 22, 2020, CalciMedica Inc. (CalciMedica), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, announced it has raised $15 million in a Series C financing round to support ongoing clinical trials in patients with COVID-19 pneumonia and commercial manufacturing of Auxora, the company’s lead drug candidate. The round was led by Valence Life Sciences, LLC with participation from new investors Bering Capital, Mesa Verde Venture Partners, and existing investor Sanderling Ventures. Wilson Sonsini Goodrich & Rosati represented CalciMedica in the transaction.
Learn More
Client Highlights
D.C. Circuit Affirms District Court Ruling in Censorship Lawsuit
On May 27, 2020, the United States Court of Appeals for the District of Columbia issued a decision affirming the dismissal of a putative class action brought against Twitter, Google, Facebook, and Apple by the conservative organization Freedom Watch and journalist Laura Loomer. This was one of a number of recent cases targeting online services for alleged bias against conservative content. Wilson Sonsini Goodrich & Rosati represented Twitter in the matter.
Learn More
Client Highlights
Wilson Sonsini Represents Evervault in $16 Million Fundraise
On May 21, 2020, Dublin-based start-up Evervault raised $16 million in venture capital to develop technology the company claims will recalibrate the traditional tradeoffs between privacy and regulation. Index Ventures led the round, which includes previous investors Sequoia Capital, Kleiner Perkins, and Frontline Ventures. In addition, the fundraising attracted money from a string of notable angel investors, such as Eventbrite cofounder Kevin Hartz and former Facebook chief security officer Alex Stamos. Wilson Sonsini Goodrich & Rosati represented Evervault in the transaction.
Learn More
Client Highlights
Wilson Sonsini Represents Nautilus in $76 Million Series B Funding
On May 21, 2020, Nautilus Biotechnology, a company pioneering a high-throughput, low-cost platform for analyzing and quantifying the human proteome, announced it has raised $76 million in an oversubscribed Series B offering that closed on May 18, placing the company's total funding in excess of $100 million. Wilson Sonsini Goodrich & Rosati represented Nautilus in the transaction.
Learn More
Client Highlights
HotSpot Therapeutics Completes $65 Million Series B Financing
On May 21, 2020, Boston-based HotSpot Therapeutics announced the completion of a $65 million Series B financing. The financing round was led by SR One, Limited, and included funds managed by Tekla Capital Management, MRL Venture Fund, Solasta Ventures, and Brace Pharma, along with co-founding investors Atlas Venture and Sofinnova Partners. Wilson Sonsini Goodrich & Rosati advised SR One in the financing.
Learn More
See More Leading Matters
The Entrepreneurs Report - Q1 2020

The COVID-19 pandemic has caused—and will continue to cause—much uncertainty in the worldwide financial markets. We expect to see substantial declines in the coming months in the number and aggregate dollar value of venture financings, similar to the declines during the dot-com crash in the early 2000s and during the 2008 financial crisis. We are already beginning to see in early Q2 more investor-favorable terms, in particular reduced valuations.

Read the Report
WSGR logo
Copyright © 2020 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.